-
Item new preprint
Daraxonrasib is estimated at $500,637 per QALY in pancreatic cancer at US launch price
A modelled economic evaluation of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma estimated 0.506 additional QALYs at an incremental cost of $253,171, or $500,637 per QALY at the $39,800 monthly launch price, in a preprint not yet peer reviewed.
-
Item new preprint
PCV21 would prevent 1.5–1.7 times as many pneumococcal cases as PCV20 in Japan
Combining Japanese adult invasive pneumococcal disease surveillance with a multicentre pneumonia study, the authors estimate that PCV21 would prevent 1.5–1.7 times as many pneumococcal disease cases as PCV20 among adults aged 65 and over at current 40% coverage.
-
Item new peer-reviewed
Machine learning predicted six-month mortality after Taiwanese care-home admission
An ensemble machine learning model built only from routine intake assessments in 636 Taiwanese long-term care facilities predicted death within 180 days of first admission with an AUROC of 0.90 in a held-out 2024 cohort, where 28.7% of new residents died.
-
Item new peer-reviewed
A Bayesian model extends excess-death estimation to six years, applied to New Zealand
A Bayesian hierarchical model fitted to 22 years of monthly deaths by age and sex extends expected-death estimation beyond the one-to-two-year horizon of standard methods, and in New Zealand finds few excess deaths during the pandemic and a return to pre-pandemic trends by 2025.
-
Item confirms peer-reviewed
Modelled estimates put 10.6m new cancers at 65+ in 2022, rising 75% by 2036
A secondary analysis of GLOBOCAN 2022 and GBD 2021 estimates reports 10.6 million new cancer cases and 6.0 million cancer deaths among adults aged 65 and over in 2022, with the modelled case count projected to rise 75.5% by 2036 as populations age.
-
Item refines peer-reviewed
Healthy working life expectancy at 50 averaged 11 years across 28 countries
In a 28-country cohort of 175,318 adults aged 50 and over, healthy working life expectancy at 50 was 10.98 years, 9.82 for women and 12.36 for men, with stroke associated with a 5.49-year reduction and higher health spending, governance quality and flexible work arrangements with longer spans.
